Dei Biopharma Founder Dr. Matthias Magoola has been awarded the prestigious Pharma Ratna Universe Award which is India’s most sought-after recognition in the Biopharma and healthcare sector.
The award was received on behalf of Dr. Magoola by Ms Olivia Kemigisa, Dei BioPharma Ltd head of Human Capital at the award ceremonies on April 20 at Taj Skyline, Ahmedabad, Gujarat, in India.
Pharma Ratna, organisers of the Awards, paid commendation to Dr. Magoola, in a citation, proceeding the accolade, recognising his efforts building Dei BioPharma from zero to a value of USD 2.5 billions in 2025.
“A man who made the whole of Africa proud with his visionary approach. He started his career from zero, and now he is a billionaire,”
The citation added: “His vision is to make Africa free from malaria and other dreaded diseases. He owns Africa’s largest Pharmaceutical & Biotech Company. ”
Ugandan scientist Dr. Magoola of Dei Biopharma wins a top Indian pharma award, recognized for his innovative work in pharmaceuticals and vaccines, making Uganda and Africa proud.
Pharma Ratna also praised Dr. Magoola, saying that his award was not just a personal honour for Dr. Magoola— but a proud moment for Uganda, Africa, and “every dreamer who believes in building global impact from the ground up.”
Dei Biopharma Ltd Chief Executive Officer Mr. Hitesh Upreti said Dr. Magoola’s vision of making Africa self-reliant in pharmaceuticals, vaccines, and cutting-edge biotech innovation is now resonating beyond borders.
“This award is a salute to the spirit of innovation, resilience, and purpose that Dr. Magoola embodies,” he said.
“We are grateful to Pharma Ratna Universe 2025 for recognising African excellence on this global stage. We are even more committed now—to rise higher, reach farther, and serve better,” he said.
The award comes in when President Museveni recently applauded Dr. Magoola for the extraordinary achievements in medical innovation, following the filing of over 100 patents with the United States Patent and Trademark Office (USPTO) for treatments targeting a wide range of diseases.
Museveni revealed he had met with Dr. Magoola to receive updates on the company’s groundbreaking projects and expressed admiration for the scale and ambition of Dei Biopharma’s work, which includes research and development of treatments for cancer, HIV, Alzheimer’s, malaria, tuberculosis, and diabetes.
“I am happy to learn that he has filed over 100 patents with the United States Patent Office for treating different diseases… some of which have been granted,” Museveni said.
Museveni affirmed the government’s commitment to facilitating the necessary regulatory processes to ensure Dei Biopharma’s drugs can be licensed and produced locally for both domestic and international markets.
“The government will support his company with the necessary accreditation requirements in order to obtain licenses for drugs to be produced locally for use in global markets,” he assured.
The President’s endorsement follows growing national and international attention on Dei Biopharma, particularly after Dr. Magoola secured a U.S. patent for an innovative cancer treatment drug.
